PASG (Passage Bio) Ending Cash Position: $33.34 Mil (As of Mar. 2026)


PASG Passage Bio Inc PASG
29 GF Score
Price $4.62
! 2 Warning Signs
View Full Analysis

What is Passage Bio Ending Cash Position?

Passage Bio PASG -2.97% 29 Ending Cash Position is $33.34 Mil as of Mar. 2026. GuruFocus rates PASG with a GF Score™ of 29/100. The stock has 2 warning signs investors should review.

Passage Bio's Ending Cash Position for the quarter that ended in Mar. 2026 was $33.34 Mil.

Passage Bio's quarterly Ending Cash Position declined from Sep. 2025 ($52.77 Mil) to Dec. 2025 ($46.30 Mil) and declined from Dec. 2025 ($46.30 Mil) to Mar. 2026 ($33.34 Mil).

Passage Bio's annual Ending Cash Position increased from Dec. 2023 ($21.71 Mil) to Dec. 2024 ($37.57 Mil) and increased from Dec. 2024 ($37.57 Mil) to Dec. 2025 ($46.30 Mil).

Passage Bio Ending Cash Position Related Terms

Passage Bio Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Passage Bio's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Passage Bio Ending Cash Position Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Ending Cash Position
Get a 7-Day Free Trial 128.97 34.60 21.71 37.57 46.30

Passage Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 63.36 57.63 52.77 46.30 33.34
PASG
29GF Score
Passage Bio Inc PASG
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Passage Bio Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Passage Bio's Ending Cash Position for the fiscal year that ended in Dec. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=37.573+8.73
=46.30

Passage Bio's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=46.303+-12.967
=33.34

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $33.34 Mil mean?
Passage Bio (PASG) has a Ending Cash Position of $33.34 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Passage Bio and its competitors.
Is Passage Bio's Ending Cash Position too high?
Passage Bio's current Ending Cash Position is $33.34 Mil. Overall, Passage Bio has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Passage Bio's Ending Cash Position compare to CTXR and HIND?
Passage Bio's Ending Cash Position of $33.34 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Passage Bio and its competitors. Passage Bio's current Ending Cash Position is $33.34 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Passage Bio stock overvalued right now?
Passage Bio (PASG) has a current Ending Cash Position of $33.34 Mil. The current Ending Cash Position is $33.34 Mil. Passage Bio's overall GF Score™ is 29/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Passage Bio (PASG), the current Ending Cash Position is $33.34 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Passage Bio Business Description

Address 2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.
29GF Score

Get the complete analysis for PASG

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.62
Price